James Investment Research’s Corcept Therapeutics CORT Stock Holding History

James Investment Research’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49M	Hold	17,122	–	–	0.15%	136
2026 Q1	$690K	Buy	17,122 +24	+0.1%	+$897	0.08%	216
2025 Q4	$595K	Hold	17,098	–	–	0.07%	226
2025 Q3	$1.42M	Buy	17,098 +2,578	+18%	+$187K	0.16%	129
2025 Q2	$1.07M	Hold	14,520	–	–	0.13%	145
2025 Q1	$1.66M	Sell	14,520 -3,629	-20%	-$221K	0.21%	108
2024 Q4	$915K	Hold	18,149	–	–	0.11%	158
2024 Q3	$840K	Hold	18,149	–	–	0.1%	174
2024 Q2	$590K	Sell	18,149 -6	-0%	-$164	0.07%	199
2024 Q1	$457K	Sell	18,155 -10	-0.1%	-$236	0.05%	223
2023 Q4	$590K	Hold	18,165	–	–	0.07%	191
2023 Q3	$495K	Hold	18,165	–	–	0.07%	192
2023 Q2	$404K	Hold	18,165	–	–	0.05%	203
2023 Q1	$393K	Buy	18,165 +5,820	+47%	+$128K	0.05%	209
2022 Q4	$251K	Buy	12,345 +4,294	+53%	+$108K	0.04%	238
2022 Q3	$206K	Hold	8,051	–	–	0.03%	257
2022 Q2	$191K	Buy	+8,051	New	+$175K	0.03%	260
2017 Q4	–	Sell	-117,400	Closed	-$2.27M	–	783
2017 Q3	$2.27M	Buy	+117,400	New	+$1.75M	0.08%	212

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

James Investment Research's CORT Position: Q2 2026 in Review

James Investment Research held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 17,122 shares worth $1.49M. The position accounts for 0.15% of the portfolio, ranked #136.

James Investment Research first reported a position in CORT in Q3 2017 and has held it in 18 quarters since. The position peaked at $2.27M in Q3 2017. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

James Investment Research held 17,122 shares of Corcept Therapeutics worth $1.49M as of Q2 2026.
James Investment Research left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.15% of James Investment Research's portfolio in Q2 2026, its #136 holding.
James Investment Research first reported a position in Corcept Therapeutics in Q3 2017 and has held it in 18 quarters since.
James Investment Research's Corcept Therapeutics position peaked at $2.27M in Q3 2017.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.